Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1.

Clinical infectious diseases : an official publication of the Infectious Diseases Society of America - 1 Jan 2013

Kieran Jennifer, Schmitz Susanne, O'Leary Aisling, Walsh Cathal, Bergin Colm, Norris Suzanne, Barry Michael

Abstract excerpt

BACKGROUND: The licensing of direct-acting antivirals heralds a new era in the treatment of hepatitis C virus (HCV) genotype 1. We undertook a mixed treatment comparison to examine the relative efficacy among current treatments for HCV. METHODS: A systematic literature review identified relevant studies. Meta-analyses were planned in treatment-naive and treatment-experienced patients. Study arms that evaluated...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents
Share to Genotype

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Hepacivirus

Share to Hepatitis C

Share to Oligopeptides

Share to Proline

Share to Recurrence

Share to Treatment Outcome

Source

Identifiers

PMID: 23074309
DOI: 10.1093/cid/cis880

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The relative efficacy of boceprevir and telaprevir in the treatment of hepatitis C virus genotype 1.PMID 23074309Read ↗

Boceprevir and telaprevir for the treatment of chronic hepatitis C genotype 1 infection: an indirect comparison meta-analysisSemantic proximity Read ↗

Direct-acting antiviral therapies for hepatitis C genotype 1 infection: a multiple treatment comparison meta-analysisSemantic proximity Read ↗

Efficacy of telaprevir and boceprevir in treatment-naïve and treatment-experienced genotype 1 chronic hepatitis C patients: an indirect comparison using Bayesian network meta-analysis.Semantic proximity Read ↗

Similar effectiveness of boceprevir and telaprevir treatment regimens for hepatitis C virus infection on the basis of a nationwide study of veterans.Semantic proximity Read ↗

Efficacy and tolerability of telaprevir for chronic hepatitis virus C genotype 1 infection: a meta-analysis.Semantic proximity Read ↗

The efficacy and safety of telaprevir-based regimens for treating chronic hepatitis C virus genotype 1 infection: a meta-analysis of randomized trials.Semantic proximity Read ↗

Effectiveness of telaprevir or boceprevir in treatment-experienced patients with HCV genotype 1 infection and cirrhosis.Semantic proximity Read ↗

Triple therapy for HCV genotype 1 infection: telaprevir or boceprevir?Semantic proximity Read ↗

Efficacy and safety of telaprevir and boceprevir in patients with hepatitis C genotype 1: a meta-analysis.Semantic proximity Read ↗

UK consensus guidelines for the use of the protease inhibitors boceprevir and telaprevir in genotype 1 chronic hepatitis C infected patients.Semantic proximity Read ↗

Triple therapy with boceprevir or telaprevir for treatment naïve HCV patients.Semantic proximity Read ↗

Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.